Compare Eni SpA (E) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Enveric Biosciences Inc — how do they compare? Eni SpA trades at $55.41 (market cap $78.10B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Eni SpA is far larger — about 11674.1× Enveric Biosciences Inc's market cap, and Eni SpA pays a 4.52% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Enveric Biosciences Inc for 14 Days on average.
| E | ENVB | |
|---|---|---|
Market Cap | $78.10B | $6.69M |
Volume | 296,516 | 41,141 |
Sector | Energy | Health |
52-Week High | $57.61 | $10.80 |
52-Week Low | $34.03 | $1.27 |
Typical Hold Time | 53 Days | 14 Days |
Enterprise Value | $102.75B | -$1.60M |
Dividend Yield | 4.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $55.62, up 1.96% today, amid a bearish technical signal. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97% in 2026. The company maintains solid cash flow and a low P/E of 12.53. Recent news highlights expansion in humanoid robotics, LNG projects in Argentina, and fuel discounts in Italy, indicating strategic diversification and customer support initiatives.
The outlook is mixed; valuation appears attractive with low multiples, and analyst consensus leans hold (61.53%). However, declining revenue, recent earnings misses, and bearish technicals pose near-term risks. Upside depends on execution of new projects and stabilization of energy markets, while volatility in oil prices remains a key sensitivity.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
